Form 4: Voyager Therapeutics Director James Geraghty Granted 24,000 Stock Options

Voyager Therapeutics, Inc. Director James A. Geraghty was granted 24,000 stock options with an exercise price of $3.28 as part of the company's 2025 Stock Incentive Plan.

Summary

• James A. Geraghty, a Director at Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options.
• The stock options have an exercise price of $3.28 per share.
• The grant date and vesting commencement date for these options was June 3, 2025.
• The options are set to expire on June 3, 2035.
• This grant was made pursuant to the company's 2025 Stock Incentive Plan and is consistent with its director compensation policy.
• The shares underlying the option will vest upon the earlier of the one-year anniversary of the vesting commencement date or the date of the next annual meeting of stockholders, subject to Mr. Geraghty's continued service as a director.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with long-term shareholder value, reflecting standard corporate governance practices. It is generally viewed as neutral to slightly positive.

Positives

• The grant of stock options to Director James A. Geraghty aligns his financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The transaction is part of a pre-approved 2025 Stock Incentive Plan and director compensation policy, indicating structured and transparent corporate governance practices.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if and when these options are exercised, although this is a standard aspect of equity compensation.

Risks

• No specific operational or financial risks related to the company's business are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The granted stock options are scheduled to vest upon the earlier of the one-year anniversary of the grant date (June 3, 2025) or the date of the next annual meeting of stockholders, contingent on James A. Geraghty's continued service as a director.

Management Comments

• The document states that the stock option was issued "pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy."

Industry Context

Granting stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, as well as across many publicly traded companies, serving as a key mechanism to attract and retain qualified board members and align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options as part of director compensation is a widely accepted standard across industries, including biotechnology.
• While specific grant sizes and exercise prices vary by company size, performance, and compensation philosophy, this type of equity award is a fundamental component of executive and director remuneration packages designed to incentivize performance and align interests with shareholders.
• No specific comparable companies, projects, or quantitative results are mentioned in this filing to allow for a detailed, direct comparison of the grant size or terms against industry peers.

Corporate Governance

Related Party Transactions

• The grant of stock options to James A. Geraghty, a Director of Voyager Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• **Shareholders:** Potential for future dilution if options are exercised, but also benefits from increased alignment of the director's interests with long-term company performance and value creation.
• **Director (James A. Geraghty):** Receives equity compensation, incentivizing continued service and performance within the company.

Next Steps

• The stock options will vest upon the earlier of June 3, 2026 (one-year anniversary of grant) or the date of the next annual meeting of stockholders, subject to continued service by James A. Geraghty.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, James A. Geraghty, 2025 Stock Incentive Plan